Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03749018
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:28.982635+00:00
Published At
2026-02-06T00:00:00+00:00
Record Updated At
2026-02-06
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Aggressive Non-Hodgkin Lymphoma", "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Indolent Non-Hodgkin Lymphoma", "Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-06"
protocolSection.identificationModule.nctId
"NCT03749018"
protocolSection.identificationModule.officialTitle
"A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin\u0027s Lymphoma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Aggressive Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • High Grade B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Indolent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Transformed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.